Liver Cirrhosis
Conditions
Brief summary
This study is aim to compare ROTEM and TEG guided coagulopathy correction in cirrhosis with non- variceal bleed.There are no other study in literature to compare this two group in cirrhosis with non-variceal bleed.This study will also assess the volume of blood product transfused with this two groups and it will compare among two groups.This will lessen the blood product transfusion and risk of transfusion relatedated complication.
Detailed description
AIM:- To compare Rotational thrombo- elastometry vs Thrombo- elastography as a guide for blood component transfusion in patients of Cirrhosis with nonvariceal bleeding. Methodology:- After fulfilling all inclusion and exclusion criteria, patients were randomized to either the TEG or ROTEM group in a 1:1 proportion. Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid Study population: patients with Cirrhosis of liver with nonvariceal bleeding Study design: Randomized controlled trial Study period: 1 years after ethical clearance Sample size: Assuming that total volume of FFP used in TEG 760 ± 370 and further in ROTEM volume used 510±275 with α 5% power 90, we need to enrol 72 cases. Further assuming 10% inadequacy We had decided to enroll a total of 80 patients, 40 in each group.The allocation will be done randomly by block randomization method. Monitoring and assessment: All the parameters of the objective and also noted any adverse effects. STATISTICAL ANALYSIS: The data will be entered in Microsoft excel and will be analyzed using SPSS version 22. The categorical data will be analyzed using Chi square/Fissure test. Exact test and continuous data will be compiled using t-test. Besides this the univariate and multivariate survival analysis will be carried out using Cox regression method. Kaplan-Meier technique will be applied for further analysis. P-value\<0.05 will be considered as significant. Adverse effects:Transfusion related complication Stopping rule: If patient decided to withdraw from study
Interventions
DIAGNOSTIC_TESTROTEM
In ROTEM group if CT EXTEM \>80S FFP at dose of 10ml/kg or PCC 20-25IU/kg ,if MCF EXTEM \<35 and MCF FIBTEM \<8 CRYO or Fibrinogen concentrate, if MCF EXTEM\<35 and MCF FIBTEM \>8 Platelet, CL LY\>50 Trenaxemic acid
DIAGNOSTIC_TESTThromboelastography
Patients in the TEG group received blood components using the following triggers: FFP at a dose of 10 mL/kg of ideal body weight when reaction time (R time) was greater than 10 minutes; a single-donor apheresis platelet (SDAP) unit, which corresponds to approximately 6 to 8 pooled units of PLTs, transfused when the maximum amplitude (MA) was less than 55 mm; and cryoprecipitate (5 pooled units) transfused when the alpha angle was less than 45°.
Sponsors
Institute of Liver and Biliary Sciences, India
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patients with Cirrhosis of any etiology 2. Age between 18 and 80 years; 3. Presenting with nonvariceal upper GI bleeding (diagnosed after doing upper GI endoscopy, which showed ongoing 4. bleed form a nonvariceal source); and 5. Significant coagulopathy assessed by CCTs (INR \> 1.8 and/or PLTs \< 50 × 109/L).
Exclusion criteria
1. Variceal bleed 2. Post Variceal ligation ulcer bleed 3. Previous or current thrombotic events defined as any documented blood clot in a venous or arterial vessel; 4. Anti-PLT or anticoagulant therapy at the time of enrollment or that had been discontinued less than 7 days before evaluation for the study; 5. Pregnancy 6. Significant cardiopulmonary diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cumulative volume of FFP transfused at Day 5. | Day 5 |
Secondary
| Measure | Time frame |
|---|---|
| Cumulative volume of Platelet in both groups | 6 weeks |
| Cumulative volume of Trenaxemic acid Transfusion related reactions in both groups | 6 weeks |
| Cumulative volume of Cryoprecipitate in both groups | 6 weeks |
| Duration of hospital stay in both groups | 6 weeks |
| Survival in both groups at 6 weeks | 6 weeks |
| Duration of intensive care unit (ICU) in both groups | 6 weeks |
Countries
India
Contacts
Primary ContactDr Saurav Paul, MD
Outcome results
None listed